DGAP-News

PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS DR. DR. IRINA ANTONIJEVIC AND DR. CHRIS TANNER TO THE SUPERVISORY BOARD - Seite 2

About Dr. Chris Tanner

Dr. Chris Tanner was a member of the Executive Board since 2005 and has been a member of the Supervisory Board of Cosmo Pharmaceuticals N.V. since 2006 for which he conducted the IPO as Chief Financial Officer and Head of Investor Relations. In 2015, Cosmo span off the daughter Cassiopea SpA where he also acts as Chief Financial Officer and Head of Investor Relations. Moreover, he is a member of the board of directors or advisory board (Beirat) of listed DKSH AG, Private Equity Holding AG and the private medtec companies Qvanteq AG and Joimax GmbH. From 1998 to 2001, he was a partner of Dr. Ernst Mueller-Moehl and co-founder of the 20 Minutes group of newspapers and founded A&A Active Investor, a SIX-listed investment company. From 1992 to 1998, he was the Head of Corporate Finance & Capital Markets at UBS in Zurich, and from 1976 to 1991 he had various functions in the Corporate Banking Department at UBS in Zurich, Madrid and Los Angeles. Dr. Tanner has a PhD in economics and a diploma as economist from the University of St. Gallen.

About PAION

PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in Phase III clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its ongoing clinical development program in procedural sedation. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anesthesia was completed in Japan and PAION is preparing filing in Japan. In the EU, PAION is currently planning to continue the clinical development program. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam.